CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Phio Pharmaceuticals Corp. - PHIO CFD

0.92
12.38%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.06
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 1.05
Open* 1.03
1-Year Change* -80.04%
Day's Range* 0.91 - 1.03
52 wk Range 0.61-12.27
Average Volume (10 days) 90.31K
Average Volume (3 months) 12.24M
Market Cap 1.61M
P/E Ratio -100.00K
Shares Outstanding 2.44M
Revenue N/A
EPS -8.17
Dividend (Yield %) N/A
Beta 1.30
Next Earnings Date Mar 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 29, 2024 1.05 0.09 9.38% 0.96 1.08 0.96
Feb 28, 2024 0.95 0.00 0.00% 0.95 0.95 0.92
Feb 27, 2024 0.93 0.03 3.33% 0.90 0.94 0.88
Feb 26, 2024 0.89 0.06 7.23% 0.83 0.92 0.83
Feb 23, 2024 0.80 -0.02 -2.44% 0.82 0.82 0.75
Feb 22, 2024 0.81 0.12 17.39% 0.69 0.86 0.69
Feb 21, 2024 0.73 0.05 7.35% 0.68 0.73 0.68
Feb 20, 2024 0.73 0.06 8.96% 0.67 0.77 0.67
Feb 16, 2024 0.63 0.01 1.61% 0.62 0.64 0.61
Feb 15, 2024 0.63 -0.02 -3.08% 0.65 0.66 0.61
Feb 14, 2024 0.64 0.00 0.00% 0.64 0.65 0.62
Feb 13, 2024 0.63 0.00 0.00% 0.63 0.65 0.62
Feb 12, 2024 0.66 0.09 15.79% 0.57 0.67 0.56
Feb 9, 2024 0.57 -0.03 -5.00% 0.60 0.60 0.54
Feb 8, 2024 0.58 0.02 3.57% 0.56 0.60 0.56
Feb 7, 2024 0.57 -0.01 -1.72% 0.58 0.58 0.56
Feb 6, 2024 0.58 0.00 0.00% 0.58 0.60 0.57
Feb 5, 2024 0.56 -0.01 -1.75% 0.57 0.58 0.55
Feb 2, 2024 0.60 0.05 9.09% 0.55 0.61 0.55
Feb 1, 2024 0.58 0.01 1.75% 0.57 0.60 0.53

Phio Pharmaceuticals Corp. Events

Time (UTC) Country Event
Wednesday, March 20, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 Phio Pharmaceuticals Corp Earnings Release
Q4 2023 Phio Pharmaceuticals Corp Earnings Release

Forecast

-

Previous

-
Thursday, May 9, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Phio Pharmaceuticals Corp Earnings Release
Q1 2024 Phio Pharmaceuticals Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0.021 0.138
Revenue 0 0.021 0.138
Total Operating Expense 11.462 13.278 8.793 9.008 7.502
Selling/General/Admin. Expenses, Total 4.45 4.625 4.362 4.708 3.176
Research & Development 7.012 8.886 4.431 4.3 4.326
Operating Income -11.462 -13.278 -8.793 -8.987 -7.364
Interest Income (Expense), Net Non-Operating -0.009
Other, Net -0.018 -0.001 0.079 0.004
Net Income Before Taxes -11.48 -13.287 -8.794 -8.908 -7.36
Net Income After Taxes -11.48 -13.287 -8.794 -8.908 -7.36
Net Income Before Extra. Items -11.48 -13.287 -8.794 -8.908 -7.36
Net Income -11.48 -13.287 -8.794 -8.908 -7.36
Total Adjustments to Net Income
Income Available to Common Excl. Extra. Items -11.48 -13.287 -8.794 -8.908 -7.36
Income Available to Common Incl. Extra. Items -11.48 -13.287 -8.794 -8.908 -7.36
Diluted Net Income -11.48 -13.287 -8.794 -8.908 -7.36
Diluted Weighted Average Shares 1.13657 1.06919 0.38226 0.0384 0.01067
Diluted EPS Excluding Extraordinary Items -10.1006 -12.4271 -23.0051 -231.984 -689.565
Diluted Normalized EPS -10.1006 -12.6451 -23.0051 -231.984 -689.565
Unusual Expense (Income) -0.233 0
Total Extraordinary Items
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 2.547 3.602 2.73 3.571 2.521
Selling/General/Admin. Expenses, Total 1.164 1.468 1.116 1.063 1.217
Research & Development 1.383 2.134 1.614 2.508 1.304
Unusual Expense (Income)
Operating Income -2.547 -3.602 -2.73 -3.571 -2.521
Interest Income (Expense), Net Non-Operating
Net Income Before Taxes -2.549 -3.602 -2.731 -3.576 -2.531
Net Income After Taxes -2.549 -3.602 -2.731 -3.576 -2.531
Net Income Before Extra. Items -2.549 -3.602 -2.731 -3.576 -2.531
Net Income -2.549 -3.602 -2.731 -3.576 -2.531
Income Available to Common Excl. Extra. Items -2.549 -3.602 -2.731 -3.576 -2.531
Income Available to Common Incl. Extra. Items -2.549 -3.602 -2.731 -3.576 -2.531
Diluted Net Income -2.549 -3.602 -2.731 -3.576 -2.531
Diluted Weighted Average Shares 1.72849 1.14221 1.13903 1.13853 1.13818
Diluted EPS Excluding Extraordinary Items -1.4747 -3.15353 -2.39765 -3.1409 -2.22372
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -1.4747 -3.15353 -2.39765 -3.1409 -2.22372
Other, Net -0.002 0 -0.001 -0.005 -0.01
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 12.446 24.727 15.164 7.3 15.15
Cash and Short Term Investments 11.781 24.057 14.244 6.934 14.879
Cash & Equivalents 11.781 24.057 14.244 6.934 14.879
Prepaid Expenses 0.615 0.62 0.87 0.316 0.221
Other Current Assets, Total 0.05 0.05 0.05 0.05 0.05
Total Assets 12.814 25.17 15.739 8.039 15.322
Property/Plant/Equipment, Total - Net 0.344 0.416 0.557 0.721 0.172
Property/Plant/Equipment, Total - Gross 1.519
Accumulated Depreciation, Total -1.175
Note Receivable - Long Term
Other Long Term Assets, Total 0.024 0.027 0.018 0.018 0
Total Current Liabilities 1.939 3.068 2.196 1.88 1.744
Accounts Payable 0.779 0.283 0.728 0.809 0.55
Accrued Expenses 1.16 2.785 1.468 1.071 1.194
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.97389 3.238 2.722 2.291 1.744
Total Long Term Debt 0 0 0.231 0 0
Total Equity 10.8401 21.932 13.017 5.748 13.578
Preferred Stock - Non Redeemable, Net 0.002 0 0 0 0
Common Stock 0.00011 0.001 0.001 0.001 0.002
Additional Paid-In Capital 139.218 138.831 116.629 100.566 99.487
Retained Earnings (Accumulated Deficit) -128.38 -116.9 -103.613 -94.819 -85.911
Total Liabilities & Shareholders’ Equity 12.814 25.17 15.739 8.039 15.322
Total Common Shares Outstanding 1.13902 1.12787 0.48173 0.05578 0.02854
Total Preferred Shares Outstanding
Other Liabilities, Total 0.03489 0.17 0.295 0.411
Long Term Debt 0 0.231
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 9.328 12.035 9.404 12.446 15.377
Cash and Short Term Investments 8.407 11.307 9.035 11.781 14.484
Cash & Equivalents 8.407 11.307 9.035 11.781 14.484
Prepaid Expenses 0.871 0.678 0.319 0.615 0.843
Other Current Assets, Total 0.05 0.05 0.05 0.05 0.05
Total Assets 9.539 12.296 9.707 12.814 15.791
Property/Plant/Equipment, Total - Net 0.208 0.255 0.297 0.344 0.39
Other Long Term Assets, Total 0.003 0.006 0.006 0.024 0.024
Total Current Liabilities 2.326 2.392 2.396 1.939 2.194
Accounts Payable 0.173 0.641 0.902 0.779 0.543
Accrued Expenses 2.153 1.751 1.494 1.16 1.651
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 2.326 2.392 2.396 1.97389 2.264
Total Long Term Debt 0 0 0 0 0
Long Term Debt
Other Liabilities, Total 0 0 0.03489 0.07
Total Equity 7.213 9.904 7.311 10.8401 13.527
Preferred Stock - Non Redeemable, Net 0 0 0 0.002 0
Common Stock 0.00023 0.0002 0.00012 0.00011 0.001
Additional Paid-In Capital 144.524 144.435 139.293 139.218 139.175
Retained Earnings (Accumulated Deficit) -137.311 -134.531 -131.982 -128.38 -125.649
Total Liabilities & Shareholders’ Equity 9.539 12.296 9.707 12.814 15.791
Total Common Shares Outstanding 2.30739 1.98521 1.15058 1.13902 1.13895
Other Equity, Total -0.00023 -0.0002 -0.00012
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -11.48 -13.287 -8.794 -8.908 -7.36
Cash From Operating Activities -12.129 -11.858 -8.802 -8.645 -7.52
Cash From Operating Activities 0.071 0.075 0.072 0.067 0.081
Non-Cash Items 0.536 0.364 0.247 0.409 0.282
Changes in Working Capital -1.256 0.99 -0.327 -0.213 -0.523
Cash From Investing Activities -0.121 -0.051 -0.019 -0.072 -0.005
Capital Expenditures -0.121 -0.051 -0.019 -0.072 -0.005
Other Investing Cash Flow Items, Total 0
Cash From Financing Activities -0.026 21.722 16.131 0.772 18.823
Issuance (Retirement) of Stock, Net 0 21.723 15.944 0.781 18.823
Net Change in Cash -12.276 9.813 7.31 -7.945 11.298
Deferred Taxes 0
Cash Interest Paid 0.008 0.006 0 0.003
Financing Cash Flow Items -0.026 -0.001 -0.017 -0.003
Issuance (Retirement) of Debt, Net 0 0.204 -0.006
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -3.602 -11.48 -8.749 -5.173 -2.642
Cash From Operating Activities -2.708 -12.129 -9.424 -5.898 -3.469
Cash From Operating Activities 0.016 0.071 0.056 0.041 0.022
Non-Cash Items 0.142 0.536 0.463 0.329 0.216
Changes in Working Capital 0.736 -1.256 -1.194 -1.095 -1.065
Cash From Investing Activities 0 -0.121 -0.121 -0.114 -0.104
Capital Expenditures 0 -0.121 -0.121 -0.114 -0.104
Cash From Financing Activities -0.038 -0.026 -0.028 -0.025 -0.025
Financing Cash Flow Items -0.036 -0.026 -0.028 -0.025 -0.025
Issuance (Retirement) of Stock, Net -0.002 0 0 0 0
Net Change in Cash -2.746 -12.276 -9.573 -6.037 -3.598
Issuance (Retirement) of Debt, Net
Cash Interest Paid

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Phio Pharmaceuticals Corp. Company profile

About Phio Pharmaceuticals Corp

Phio Pharmaceuticals Corp. is a biotechnology company. The Company is focused on developing immuno-oncology therapeutics based on its self-delivering ribonucleic acid interface (RNAi) INTASYL therapeutic platform. The Company has developed a product platform based on its INTASYL technology that allows selective non-genetically modified programming of adoptive cell therapy (ACT) cells and of the tumor micro-environment (TME), resulting in reduced immune inhibition and in improved immunotherapy. Its lead product candidate, PH-762, is an INTASYL compound that targets the checkpoint protein PD-1, which acts as a type of switch that prevents T cells from attacking certain cells, such as cancer cells, in the body. Its second product candidate, PH-894, is an INTASYL compound that targets BRD4, which is a regulator of gene expression impacting cell differentiation. It is also developing PH-804, which targets the suppressive immune receptor TIGIT.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Phio Pharmaceuticals Corp revenues was not reported. Net loss increased 55% to $9.8M. Higher net loss reflects Research & Development Expenses - Balanc increase from $3.2M to $7M (expense), Labor & Related Expenses in SGA increase from $93K to $262K (expense), Stock-based Compensation in R&D increase from $17K to $80K (expense).

Equity composition

Common stock $.0001 Par, 1500M shares auth., 100,439,841 issd. Insider own 52.94%. 07/13, 1-for-30 reverse stock split. 04/16, 1-for-10 reverse stock split.

Industry: Biotechnology & Medical Research (NEC)

257 Simarano Dr Ste 101
MARLBOROUGH
MASSACHUSETTS 01752-3070
US

Income Statement

  • Annual
  • Quarterly

News

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

Federal Reserve meeting preview: strong data is making it hard to justify cutting rates

Markets expect the Fed to keep rates unchanged as strong economic data continues

11:30, 30 January 2024

People also watch

XRP/USD

0.60 Price
-0.850% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

80.34 Price
+2.790% 1D Chg, %
Long position overnight fee 0.0259%
Short position overnight fee -0.0478%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

61,575.50 Price
-0.230% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

US100

18,193.60 Price
+0.850% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading